Comparison of effective regurgitant orifice area by the PISA method and tricuspid coaptation gap measurement to identify very severe tricuspid regurgitation and stratify mortality risk.

coaptation gap effective regurgitant orifice area mortality survival very severe tricuspid regurgitation

Journal

Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388

Informations de publication

Date de publication:
2023
Historique:
received: 05 11 2022
accepted: 10 04 2023
medline: 14 5 2023
pubmed: 14 5 2023
entrez: 14 5 2023
Statut: epublish

Résumé

Various definitions of very severe (VS) tricuspid regurgitation (TR) have been proposed based on the effective regurgitant orifice area (EROA) or tricuspid coaptation gap (TCG). Because of the inherent limitations associated with the EROA, we hypothesized that the TCG would be more suitable for defining VSTR and predicting outcomes. In this French multicentre retrospective study, we included 606 patients with ≥moderate-to-severe isolated functional TR (without structural valve disease or an overt cardiac cause) according to the recommendations of the European Association of Cardiovascular Imaging. Patients were further stratified into VSTR according to the EROA (≥60 mm The relationship between the EROA and TCG was poor ( The correlation between the TCG and EROA is weak and decreases with increasing defect size. A TCG ≥10 mm is associated with increased all-cause and cardiovascular mortality and should be used to define VSTR in isolated significant functional TR.

Identifiants

pubmed: 37180795
doi: 10.3389/fcvm.2023.1090572
pmc: PMC10172668
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1090572

Informations de copyright

© 2023 Bohbot, Tordjman, Dreyfus, Le Tourneau, Lavie-Badie, Selton-Suty, Elegamandji, L'official, Fraix, Aghezzaf, Turgeon, Messika Zeitoun, Enriquez-Sarano, Coisne, Donal and Tribouilloy.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Am J Cardiol. 2021 Feb 1;140:128-133
pubmed: 33144167
Res Cardiovasc Med. 2013 Aug;2(3):121-6
pubmed: 25478507
Eur Heart J Cardiovasc Imaging. 2017 Dec 1;18(12):1342-1343
pubmed: 28977455
Eur Heart J Cardiovasc Imaging. 2019 Sep 1;20(9):1035-1042
pubmed: 30830219
Circulation. 2010 Oct 12;122(15):1505-13
pubmed: 20876436
J Am Coll Cardiol. 2021 Feb 2;77(4):e25-e197
pubmed: 33342586
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Am J Cardiol. 1999 Mar 15;83(6):897-902
pubmed: 10190406
Am Heart J. 1996 Apr;131(4):742-7
pubmed: 8721649
J Am Coll Cardiol. 2019 Dec 17;74(24):2998-3008
pubmed: 31568868
Eur Heart J Cardiovasc Imaging. 2022 Apr 18;23(5):e171-e232
pubmed: 35292799
J Am Soc Echocardiogr. 2022 Jun;35(6):664-666
pubmed: 35245669
Eur Heart J Cardiovasc Imaging. 2013 Jul;14(7):611-44
pubmed: 23733442
J Clin Med. 2022 Jan 13;11(2):
pubmed: 35054074
J Am Soc Echocardiogr. 2020 Sep;33(9):1087-1094
pubmed: 32651124
JACC Cardiovasc Imaging. 2019 Mar;12(3):491-499
pubmed: 30846123
JACC Cardiovasc Imaging. 2019 Mar;12(3):433-442
pubmed: 30121261
J Am Coll Cardiol. 2004 Feb 4;43(3):405-9
pubmed: 15013122
Prog Cardiovasc Dis. 2019 Nov - Dec;62(6):447-451
pubmed: 31707061
JACC Cardiovasc Imaging. 2019 Apr;12(4):652-664
pubmed: 30947907
Circulation. 2019 Jul 16;140(3):196-206
pubmed: 31117814
JACC Cardiovasc Imaging. 2010 Mar;3(3):235-43
pubmed: 20223419
J Am Coll Cardiol. 2017 Apr 11;69(14):1795-1806
pubmed: 28385308
JACC Cardiovasc Imaging. 2014 Dec;7(12):1185-94
pubmed: 25440592
Am J Cardiol. 2020 Oct 1;132:119-125
pubmed: 32741538
Arch Cardiovasc Dis. 2019 Oct;112(10):604-614
pubmed: 31558358
J Am Soc Echocardiogr. 2017 Apr;30(4):303-371
pubmed: 28314623
J Am Coll Cardiol. 2000 Aug;36(2):472-8
pubmed: 10933360
J Am Soc Echocardiogr. 2002 Sep;15(9):958-65
pubmed: 12221413
JACC Cardiovasc Imaging. 2021 Jun;14(6):1085-1095
pubmed: 33582056
Eur Heart J. 2022 Feb 12;43(7):561-632
pubmed: 34453165
Circ Res. 1992 May;70(5):923-30
pubmed: 1568302
Arch Cardiovasc Dis. 2020 Oct;113(10):599-606
pubmed: 32994143

Auteurs

Yohann Bohbot (Y)

Department of Cardiology, Amiens University Hospital, Amiens, France.
UR UPJV 7517, Jules Verne University of Picardie, Amiens, France.

Léa Tordjman (L)

Department of Cardiology, Amiens University Hospital, Amiens, France.

Julien Dreyfus (J)

Cardiology Department, Centre Cardiologique du Nord, Saint-Denis, France.

Thierry Le Tourneau (T)

l'institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France.

Yoan Lavie-Badie (Y)

Department of Cardiology, Rangueil University Hospital, Toulouse, France.

Christine Selton-Suty (C)

Cardiology Department CIC-EC, CHU Nancy-Brabois, Nancy, France.

Benjamin Elegamandji (B)

Cardiology Department, Centre Cardiologique du Nord, Saint-Denis, France.

Guillaume L'official (G)

CHU Rennes, Inserm, LTSI-UMR 1099, University of Rennes, Rennes, France.

Antoine Fraix (A)

Cardiology Department CIC-EC, CHU Nancy-Brabois, Nancy, France.

Samy Aghezzaf (S)

Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, University Lille, Lille, France.

Pierre Yves Turgeon (PY)

l'institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France.

David Messika Zeitoun (D)

Department of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada.

Maurice Enriquez-Sarano (M)

Valve Science Center, Minneapolis Heart Institute Foundation, Minneapolis, MN, United States.

Augustin Coisne (A)

Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, University Lille, Lille, France.
Cardiovascular Research Foundation, New York, NY, United States.

Erwan Donal (E)

CHU Rennes, Inserm, LTSI-UMR 1099, University of Rennes, Rennes, France.

Christophe Tribouilloy (C)

Department of Cardiology, Amiens University Hospital, Amiens, France.
UR UPJV 7517, Jules Verne University of Picardie, Amiens, France.

Classifications MeSH